Gilenya (Novartis) toxicity problems issue

The Institute for Safe Medicine Practices says the FDA should substantially restrict the use of Gilenya (fingolimod) from Novartis and enhance patient monitoring. Problems of widespread toxicity that were already evident in clinical testing of Gilenya are now producing strong signals in the postmarket adverse event data.